Heron Therapeutics (HRTX) Cash from Financing Activities (2010 - 2026)

Heron Therapeutics (HRTX) has 17 years of Cash from Financing Activities data on file, last reported at -$51000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 179.69% year-over-year to -$51000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (up 1341.29% YoY) and the FY2025 annual result came in at $14.4 million, up 1434.79% from the prior year.
• Cash from Financing Activities eased to -$51000.0 in Q1 2026, from $219000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $74.9 million in Q3 2022 to a low of -$637000.0 in Q1 2022.
• A 5-year average of $8.5 million and a median of $315000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 105652.11% — and 2026, when it plunged 179.69%.
• Tracing HRTX's Cash from Financing Activities over 5 years: stood at $439000.0 in 2022, then slumped by 54.67% to $199000.0 in 2023, then jumped by 112.56% to $423000.0 in 2024, then tumbled by 48.23% to $219000.0 in 2025, then sank by 123.29% to -$51000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$51000.0 (Q1 2026), $219000.0 (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.